Reports

Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.

Global Idiopathic Pulmonary Fibrosis Treatment Market: By Drug Class: Pirfenidone, Nintedanib; Regional Analysis; Historical Market and Forecast (2017-2027); Market Dynamics: SWOT Analysis, Porter’s Five Forces Analysis, EMR’s Key indicators for Demand, EMR’s Key Indicator for Price; Competitive Landscape; Industry Events and Developments

Global Idiopathic Pulmonary Fibrosis Treatment Market Outlook

The global idiopathic pulmonary fibrosis treatment market stood at USD 2.2 billion in 2020. The idiopathic pulmonary fibrosis treatment market is expected to grow at a CAGR of about 12% in the forecast period of 2022-2027, driven by the growing cases of lung diseases.

 

The industry is expected to attain a value of USD 4.3 billion by 2026. The market is being dominated by the North America and European regions.

 

Global Idiopathic Pulmonary Fibrosis Treatment Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Market Segmentation

Idiopathic pulmonary fibrosis (IPF) refers to a severe lung disease. As you breathe in, oxygen travels through tiny airbags in your lungs and into your bloodstream. This flows to the organs from there. IPF causes scar tissue to develop within the lungs, making it hard to breathe. The treatment of this disease can help in slowing down the damage to the lungs.

 

Global Idiopathic Pulmonary Fibrosis Treatment Market by Drug Class

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

The idiopathic pulmonary fibrosis treatment market can be broadly categorised based on drug class into:

  • Pirfenidone
  • Nintedanib

The EMR report looks into the regional markets for idiopathic pulmonary fibrosis like North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific.

 

Global Idiopathic Pulmonary Fibrosis Treatment Market by Region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Market Analysis

The increased prevalence of idiopathic pulmonary fibrosis (IPF) and the increasing geriatric population are the key drivers of the market. The increase in the number of people smoking cigarettes, leading to a high prevalence of IPF, is also projected to fuel the growth of the market.

 

Competitive Landscape

The report presents a detailed analysis of the following key players in the global market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

  • Boehringer Ingelheim International GmbH.
  • Merck & Co., Inc.
  • Cipla Inc.
  • F. Hoffmann-La Roche Ag
  • Others

The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.

 

REPORT FEATURES DETAILS
Base Year 2020
Historical Period 2017-2021
Forecast Period 2022-2027
Scope of the Report Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Drug Class, Region
Breakup by Drug Class Pirfenidone, Nintedanib
Breakup by Region North America, Europe, Asia Pacific, Latin America, Middle East and Africa
Market Dynamics SWOT, Porter's Five Forces, Key Indicators for Price and Demand
Competitive Landscape Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications
Companies Covered Boehringer Ingelheim International GmbH., Merck & Co., Inc., Cipla Inc., F. Hoffmann-La Roche Ag, Others
Report Price and Purchase Option Explore our purchase options that are best suited to your resources and industry needs.
Delivery Format Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
2    Report Coverage – Key Segmentation and Scope
3    Report Description

    3.1    Market Definition and Outlook
    3.2    Properties and Applications
    3.3    Market Analysis
    3.4    Key Players
4    Key Assumptions
5    Executive Summary

    5.1    Overview
    5.2    Key Drivers
    5.3    Key Developments
    5.4    Competitive Structure
    5.5    Key Industrial Trends
6    Snapshot
    6.1    Global
    6.2    Regional
7    Industry Opportunities and Challenges
8    Global Idiopathic Pulmonary Fibrosis Treatment Market Analysis

    8.1    Key Industry Highlights
    8.2    Global Idiopathic Pulmonary Fibrosis Treatment Historical Market (2017-2021) 
    8.3    Global Idiopathic Pulmonary Fibrosis Treatment Market Forecast (2022-2027)
    8.4    Global Idiopathic Pulmonary Fibrosis Treatment Market by Drug Class
        8.4.1    Pirfenidone
            8.4.1.1    Market Share
            8.4.1.2    Historical Trend (2017-2021)
            8.4.1.3    Forecast Trend (2022-2027)
        8.4.2    Nintedanib
            8.4.2.1    Market Share
            8.4.2.2    Historical Trend (2017-2021)
            8.4.2.3    Forecast Trend (2022-2027)
    8.5    Global Idiopathic Pulmonary Fibrosis Treatment Market by Region
        8.5.1    Market Share
            8.5.1.1    North America
            8.5.1.2    Europe
            8.5.1.3    Asia Pacific
            8.5.1.4    Latin America
            8.5.1.5    Middle East and Africa
9    Regional Analysis
    9.1    North America
        9.1.1    Historical Trend (2017-2021)
        9.1.2    Forecast Trend (2022-2027)
        9.1.3    Breakup by Country
            9.1.3.1    United States of America 
            9.1.3.2    Canada
    9.2    Europe
        9.2.1    Historical Trend (2017-2021)
        9.2.2    Forecast Trend (2022-2027)
        9.2.3    Breakup by Country 
            9.2.3.1    United Kingdom
            9.2.3.2    Germany
            9.2.3.3    France
            9.2.3.4    Italy
            9.2.3.5    Others
    9.3    Asia Pacific
        9.3.1    Historical Trend (2017-2021)
        9.3.2    Forecast Trend (2022-2027)
        9.3.3    Breakup by Country
            9.3.3.1    China
            9.3.3.2    Japan
            9.3.3.3    India
            9.3.3.4    ASEAN
            9.3.3.5    Australia
            9.3.3.6    Others
    9.4    Latin America
        9.4.1    Historical Trend (2017-2021)
        9.4.2    Forecast Trend (2022-2027)
        9.4.3    Breakup by Country
            9.4.3.1    Brazil
            9.4.3.2    Argentina
            9.4.3.3    Mexico
            9.4.3.4    Others
    9.5    Middle East and Africa
        9.5.1    Historical Trend (2017-2021)
        9.5.2    Forecast Trend (2022-2027)
        9.5.3    Breakup by Country
            9.5.3.1    Saudi Arabia
            9.5.3.2    United Arab Emirates
            9.5.3.3    Nigeria
            9.5.3.4    South Africa
            9.5.3.5    Others
10    Market Dynamics
    10.1    SWOT Analysis
        10.1.1    Strengths
        10.1.2    Weaknesses
        10.1.3    Opportunities
        10.1.4    Threats
    10.2    Porter’s Five Forces Analysis
        10.2.1    Supplier’s Power
        10.2.2    Buyer’s Power
        10.2.3    Threat of New Entrants
        10.2.4    Degree of Rivalry
        10.2.5    Threat of Substitutes
    10.3    Key Indicators for Demand
    10.4    Key Indicators for Price
11    Value Chain Analysis
12    Competitive Landscape

    12.1    Market Structure
    12.2    Company Profiles
        12.2.1    Boehringer Ingelheim International GmbH.
            12.2.1.1    Company Overview 
            12.2.1.2    Product Portfolio
            12.2.1.3    Demographic Reach and Achievements
            12.2.1.4    Certifications
        12.2.2     Merck & Co., Inc.
            12.2.2.1    Company Overview 
            12.2.2.2    Product Portfolio
            12.2.2.3    Demographic Reach and Achievements
            12.2.2.4    Certifications
        12.2.3    Cipla Inc.
            12.2.3.1    Company Overview
            12.2.3.2    Product Portfolio
            12.2.3.3    Demographic Reach and Achievements
            12.2.3.4    Certifications
        12.2.4    F. Hoffmann-La Roche Ag
            12.2.4.1    Company Overview
            12.2.4.2    Product Portfolio
            12.2.4.3    Demographic Reach and Achievements
            12.2.4.4    Certifications
        12.2.5    Others
13    Industry Events and Developments


List of Key Figures and Tables

1.    Global Idiopathic Pulmonary Fibrosis Treatment Market: Key Industry Highlights, 2016 and 2026
2.    Global Idiopathic Pulmonary Fibrosis Treatment Historical Market: Breakup by Drug Class (USD Billion), 2017-2021
3.    Global Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Breakup by Drug Class (USD Billion), 2022-2027
4.    Global Idiopathic Pulmonary Fibrosis Treatment Historical Market: Breakup by Region (USD Billion), 2017-2021
5.    Global Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Breakup by Region (USD Billion), 2022-2027
6.    North America Idiopathic Pulmonary Fibrosis Treatment Historical Market: Breakup by Country (USD Billion), 2017-2021
7.    North America Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Breakup by Country (USD Billion), 2022-2027
8.    Europe Idiopathic Pulmonary Fibrosis Treatment Historical Market: Breakup by Country (USD Billion), 2017-2021
9.    Europe Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Breakup by Country (USD Billion), 2022-2027
10.    Asia Pacific Idiopathic Pulmonary Fibrosis Treatment Historical Market: Breakup by Country (USD Billion), 2017-2021
11.    Asia Pacific Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Breakup by Country (USD Billion), 2022-2027
12.    Latin America Idiopathic Pulmonary Fibrosis Treatment Historical Market: Breakup by Country (USD Billion), 2017-2021
13.    Latin America Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Breakup by Country (USD Billion), 2022-2027
14.    Middle East and Africa Idiopathic Pulmonary Fibrosis Treatment Historical Market: Breakup by Country (USD Billion), 2017-2021
15.    Middle East and Africa Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Breakup by Country (USD Billion), 2022-2027
16.    Global Idiopathic Pulmonary Fibrosis Treatment Market Structure

Key Questions Answered in the Report

In 2020, the global idiopathic pulmonary fibrosis treatment market attained a value of nearly USD 2.2 billion.

The market is estimated to witness a healthy growth, expanding at a CAGR of 12% in the forecast period of 2022-2027.

The major drivers of the market include the growing cases of lung diseases, increasing geriatric population, and rising patient awareness, which is likely to propel the demand for idiopathic pulmonary fibrosis treatment.

The increasing number of smokers, which is leading to a rise in prevalence of IPF (idiopathic pulmonary fibrosis), is expected to be a key trend guiding the growth of the industry.

The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.

Pirfenidone and nintedanib are the different drug-classes of the treatment.

The major players in the industry are Boehringer Ingelheim International GmbH., Merck & Co., Inc., Cipla Inc., and F. Hoffmann-La Roche Ag, among others.

Analyst Review

The global idiopathic pulmonary fibrosis treatment market attained a value of USD 2.2 billion in 2020, driven by the growing cases of lung diseases and increasing geriatric population. Aided by the growing prevalence of IPF (idiopathic pulmonary fibrosis) and advancements in the medical sector, the market is expected to witness a further growth in the forecast period of 2022-2027, growing at a CAGR of 12%.

EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on drug-class, the market is divided into pirfenidone and nintedanib. The major regional markets for idiopathic pulmonary fibrosis treatment are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The key players in the above market include Boehringer Ingelheim International GmbH., Merck & Co., Inc., Cipla Inc., and F. Hoffmann-La Roche Ag, among others.

EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.

Purchase Full Report

Mini Report

$1499
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$2699
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

$3699
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$4699
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER